<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT FOR ISSUERS SUBJECT TO
THE</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">1934 ACT REPORTING REQUIREMENTS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, DC 20549</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Section 13 or 15(d) of the
Securities Exchange Act</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report&nbsp;&nbsp;(Date of Earliest
Event Reported): February 23, 2012</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Radient Pharmaceuticals Corporation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; line-height: 115%; text-align: center">Delaware</TD>
    <TD STYLE="width: 34%; line-height: 115%; text-align: center">001-16695</TD>
    <TD STYLE="width: 33%; line-height: 115%; text-align: center">33-0413161</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">(State&nbsp;or&nbsp;other</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">jurisdiction&nbsp;of</TD>
    <TD STYLE="line-height: 115%; text-align: center">(Commission&nbsp;File&nbsp;Number)</TD>
    <TD STYLE="line-height: 115%; text-align: center">(IRS&nbsp;Employer&nbsp;Identification&nbsp;No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">incorporation)</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">2492 Walnut Avenue, Suite 100, Tustin,
California, 92780-7039</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices
(zip code))</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">714-505-4461</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number,
including area code)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a - 12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13d-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 3.01 &ndash; Notice of Delisting
or Failure to satisfy a continued listing rule or standard; Transfer of Listing</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We received a notice from the Pink OTC
Markets Inc., dated August 23, 2011 notifying us that we were out of compliance with OTCQX Rules for U.S. Companies section 3.2.b,
which states, in essence, that our common stock must have a minimum closing bid price of $0.10 per share at least once in every
thirty consecutive trading days. If our common stock does not meet that requirement, we have 180 days to regain compliance therewith
by maintaining a $0.10 closing bid price for ten consecutive trading days during such grace period. The grace period ended on February
20, 2012 and because our common stock did not meet the closing bid price requirement, our common stock will move down from the
OTCQX tier of the OTC Markets to the OTCQB tier of the OTC Markets, as of February 22, 2012. The main difference between the OTCQB
and OTCQX is that stocks listed on the OTCQX undergo additional quality review and have different listing standards than those
on the OTCQB, although both are tiers of the OTC Markets. Our trading symbol shall remain the same.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 2.04&#9;Triggering Events that
Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The delisting of our common stock from
the OTCQX constitutes an event of default under certain of our outstanding notes, including the &ldquo;2011 Noteholders&rdquo;
(as that term is defined in our Form 8-K dated November 29, 2011). As of the date of this filing, such notes have a total outstanding
balance of approximately $13.6 million. Under the default provisions of such notes, the holders maintain the right to accelerate
the payment of the entire outstanding balance of their notes. In addition, the 2011 Noteholders have the right to demand redemption
of all of their outstanding Series B Preferred Stock. As of the date of this filing, an aggregate of 389,517 shares of Series B
Preferred Stock is outstanding. As of the date of this filing, none of the Noteholders have declared a default, requested acceleration
nor have any of the Series B Preferred Stock holders demanded redemption.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 8.01- Other Events</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have a severe working capital shortage and
are currently unable to pay our accounts payable and other obligations in the ordinary course of business.&nbsp; As at the date
of this filing, approximately $966,000 of our accounts payable is overdue. Although we are actively seeking to obtain additional
financing, there can be no assurance that such financing will be available or, if so, that such financing will be on terms that
would be beneficial to us or our shareholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To that end, we signed a term sheet with a
potential investor on February 23, 2012 that contemplates the issuance of a convertible note, in the principal amount of $3,315,000
that mature in 18 months (the &ldquo;Company Note&rdquo;). The investor proposes to pay $3,000,000 on the basis of $250,000 in
cash at closing and the balance to be evidenced by a series of investor notes that would be paid over the next 12 months. However,
such payments are subject to a number of cash payment conditions, including our registering for resale our common stock issuable
upon conversion of the Company Note. In addition, the contemplated financing is subject to various closing conditions, including
successful negotiations of final transaction documents and receiving consents and waivers from certain of our lenders and other
investors. Accordingly, this contemplated financing may not close.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If, in the near future, we are unable to complete
the contemplated financing and satisfy the investor&rsquo;s cash payment conditions, or we are unable to obtain alternative financing,
we may have to seek protection from creditors under the Federal Bankruptcy Act. Our inability to pay our debts as they become due
also constitutes an event of default under our senior notes and a mandatory redemption event under our redeemable Series B Preferred
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">This Current Report on Form 8-K
is neither an offer to sell nor the solicitation of an offer to buy our securities or any other securities and shall not constitute
an offer to sell or solicitation of offers to buy any securities.</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; font-weight: bold; text-align: justify">RADIENT PHARMACEUTICALS CORPORATION</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: justify; width: 3%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; line-height: 115%; text-align: justify; width: 47%">/s/ Douglas
    MacLellan&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; text-align: justify">Name:&nbsp;&nbsp;Douglas MacLellan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; text-align: justify">Title:&nbsp;&nbsp;&nbsp; Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Dated: February 23, 2012&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v303388_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 17144}]
{"company-data": {"conformed-name": "RADIENT PHARMACEUTICALS Corp", "cik": "0000838879", "assigned-sic": "2834", "irs-number": "330413161", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-16695", "film-number": "12634092"}, "business-address": {"street1": "2492 WALNUT AVENUE", "street2": "STE 100", "city": "TUSTIN", "state": "CA", "zip": "92780", "phone": "7145054460"}, "mail-address": {"street1": "2492 WALNUT AVENUE", "street2": "STE 100", "city": "TUSTIN", "state": "CA", "zip": "92780"}, "former-company": [{"former-conformed-name": "AMDL INC", "date-changed": "19920703"}, {"former-conformed-name": "CALIFORNIA VENTURES INC", "date-changed": "19890905"}]}
CURRENT REPORT FOR ISSUERS SUBJECT TO
THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act
Date of Report  (Date of Earliest
Event Reported): February 23, 2012
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified
in its charter)
Delaware
001-16695
33-0413161
(State or other
jurisdiction of
(Commission File Number)
(IRS Employer Identification No.)
incorporation)
2492 Walnut Avenue, Suite 100, Tustin,
California, 92780-7039
(Address of principal executive offices
(zip code))
714-505-4461
(Registrant's telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):
£
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a - 12)
£
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13d-4(c))
Item 3.01 – Notice of Delisting
or Failure to satisfy a continued listing rule or standard; Transfer of Listing
We received a notice from the Pink OTC
Markets Inc., dated August 23, 2011 notifying us that we were out of compliance with OTCQX Rules for U.S. Companies section 3.2.b,
which states, in essence, that our common stock must have a minimum closing bid price of $0.10 per share at least once in every
thirty consecutive trading days. If our common stock does not meet that requirement, we have 180 days to regain compliance therewith
by maintaining a $0.10 closing bid price for ten consecutive trading days during such grace period. The grace period ended on February
20, 2012 and because our common stock did not meet the closing bid price requirement, our common stock will move down from the
OTCQX tier of the OTC Markets to the OTCQB tier of the OTC Markets, as of February 22, 2012. The main difference between the OTCQB
and OTCQX is that stocks listed on the OTCQX undergo additional quality review and have different listing standards than those
on the OTCQB, although both are tiers of the OTC Markets. Our trading symbol shall remain the same.
Item 2.04	Triggering Events that
Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.
The delisting of our common stock from
the OTCQX constitutes an event of default under certain of our outstanding notes, including the "2011 Noteholders"
(as that term is defined in our Form 8-K dated November 29, 2011). As of the date of this filing, such notes have a total outstanding
balance of approximately $13.6 million. Under the default provisions of such notes, the holders maintain the right to accelerate
the payment of the entire outstanding balance of their notes. In addition, the 2011 Noteholders have the right to demand redemption
of all of their outstanding Series B Preferred Stock. As of the date of this filing, an aggregate of 389,517 shares of Series B
Preferred Stock is outstanding. As of the date of this filing, none of the Noteholders have declared a default, requested acceleration
nor have any of the Series B Preferred Stock holders demanded redemption.
Item 8.01- Other Events
We have a severe working capital shortage and
are currently unable to pay our accounts payable and other obligations in the ordinary course of business.  As at the date
of this filing, approximately $966,000 of our accounts payable is overdue. Although we are actively seeking to obtain additional
financing, there can be no assurance that such financing will be available or, if so, that such financing will be on terms that
would be beneficial to us or our shareholders.
To that end, we signed a term sheet with a
potential investor on February 23, 2012 that contemplates the issuance of a convertible note, in the principal amount of $3,315,000
that mature in 18 months (the "Company Note"). The investor proposes to pay $3,000,000 on the basis of $250,000 in
cash at closing and the balance to be evidenced by a series of investor notes that would be paid over the next 12 months. However,
such payments are subject to a number of cash payment conditions, including our registering for resale our common stock issuable
upon conversion of the Company Note. In addition, the contemplated financing is subject to various closing conditions, including
successful negotiations of final transaction documents and receiving consents and waivers from certain of our lenders and other
investors. Accordingly, this contemplated financing may not close.
If, in the near future, we are unable to complete
the contemplated financing and satisfy the investor's cash payment conditions, or we are unable to obtain alternative financing,
we may have to seek protection from creditors under the Federal Bankruptcy Act. Our inability to pay our debts as they become due
also constitutes an event of default under our senior notes and a mandatory redemption event under our redeemable Series B Preferred
Stock.
This Current Report on Form 8-K
is neither an offer to sell nor the solicitation of an offer to buy our securities or any other securities and shall not constitute
an offer to sell or solicitation of offers to buy any securities.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
RADIENT PHARMACEUTICALS CORPORATION
By:
/s/ Douglas
    MacLellan
Name:  Douglas MacLellan
Title:    Chief Executive Officer
Dated: February 23, 2012